Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification

C Auw-Haedrich, S E Coupland, A Kapp, A Schmitt-Gräff, R Buchen, H Witschel

Abstract

Aim—To classify ocular adnexal lymphomas according to the Revised European and American Lymphoma (REAL) classification and to determine any correlation between clinical features or histomorphological variables with the patients’ outcome.

Methods—Conventional and immunohistology were performed on representative sections of 53 specimens of 46 patients with ocular adnexal lymphoma. The antibodies used were CD20, BCL-2, CD21, CD23, CD43, CD3, CD5, p53, cyclin D1, pan-cytokeratin, kappa, lambda, IgD, and IgM. The growth fraction of the tumours was determined using the MIB-1 antibody directed against the Ki-67 antigen. Clinical follow up data regarding the outcome were obtained from the treating physicians and/or hospital files. The Student’s t test and log rank test were used for statistical analysis.

Results—The patient collective consisted of 29 females and 17 males with an age range of 32–89.7 years (average 63 years). Almost all specimens represented B cell non-Hodgkin’s lymphomas: extranodal marginal zone lymphoma (EMZL) (n=38), diffuse large cell B cell lymphoma (n=5), lymphoplasmocytic lymphoma/imimmunocytoma (n=2), mantle cell lymphoma (n=2), follicle centre lymphoma (n=1), and plasmacytoma (n=1). One case of a secondary anaplastic large cell lymphoma of T cell type (T-ALCL) was diagnosed. The majority of the patients had stage I disease. A variety of therapeutic regimens was administered, the main form of treatment being radiotherapy. The average follow up time was 85 months. Complete remission was achieved in 24 patients (10 after excision alone, eight after radiotherapy alone, three after combined excision and radiotherapy, one after chemotherapy alone, and two after combined radiotherapy and chemotherapy). 12 patients died of causes related to lymphoma; in one patient the cause of death was unknown. Six patients had persistent tumour at final follow up and two patients were lost to follow up. The stage at presentation, as well as the lymphoma malignancy category, had a significant correlation with the final course of the disease (p=0.0001 and p=0.03, respectively). A significant correlation was also noted between the final outcome (p<0.05) and tumour cell expression for Ki-67 antigen and p53 protein.

Conclusion—67% of patients with ocular adnexal lymphoma had EMZL. The stage at presentation had a significant influence on the final outcome. MIB-1 and p53 expression by the tumour cells proved to be important immunohistochemical markers concerning the prognosis. It is suggested that, following thorough staging investigations, primary EMZL (stage I) (if accessible) should be treated with excisional biopsy and subsequent low dose radiotherapy. Primary diffuse large cell B cell lymphoma of the ocular adnexa requires at least similar therapeutic measures and regular intensive follow up.

Ocular adnexal lymphomas (OAL) represent lymphatic neoplasms which develop as primary or secondary tumour manifestations in the conjunctiva, lid, orbit, lacrimal gland, or lacrimal sac. Most patients with OAL present with localised disease (stage I) in the 6th or 7th decade of life.

Many OAL were previously known in the literature as “benign lymphoma” or “pseudolymphomas”, as most do contain small monomorph lymphocytic infiltrates similar to reactive lymphoid hyperplasia (RLH) and have a favourable course. 2 The criteria previously used to distinguish between small cell lymphoma and RLH were not clearly defined and were based mainly on cellular morphology. It was only with the advent of immunohistochemistry and molecular biological studies, such as polymerase chain reaction, together with the recognition of the mucosa associated lymphatic tissue (MALT) lymphoma as an entity in 1983 by Isaacson and Wright, 3 that the distinction between the two entities became clearer.

Previous studies 4 5 have classified OAL using the European Kiel classification 6 and the American “working formulation”. 7 More recent studies have applied the Revised European American Lymphoma (REAL) classification, which is probably more appropriate owing to its inclusion of both nodal and extranodal lymphomas. The REAL classification subdivides lymphomas on the basis of histological, immunophenotypic, and genetic features. 1 It includes elements of both the European Kiel classification 6 and the American “working formulation”. 7 According to the REAL classification, the most common subtype of lymphoma in the ocular adnexa is the extranodal marginal zone B cell lymphoma (EMZL). 2 10 The term EMZL was proposed by

University Eye Hospital, Freiburg, Germany
C Auw-Haedrich
A Kapp
R Buchen
H Witschel

Department of Pathology, UKBF, Berlin, Germany
S E Coupland

Department of Pathology, Freiburg, Germany
A Schmitt-Gräff

Correspondence to:
C Auw-Haedrich,
Kilianstrasse 5, D-79106 Freiburg, Germany
auw@aug.ukl.uni-freiburg.de

Accepted for publication 26 May 2000
the REAL classification to incorporate MALT lymphomas with or without a mucosa, as it since had become apparent that they can also occur in locations where neither a mucosa nor an epithelium is present, such as the orbit. In total, EMZL comprise together approximately 10–33% of all lymphomas.10 Few investigations have been undertaken to address the long term outcome of OAL classified according to the REAL classification.2 10 12 Recent studies revealed a significant correlation between clinical features and immunohistochemical markers with the long term outcome of OAL,10 whereas earlier10 and also recent studies11 have not. The aim of the current study was to reclassify OAL on file in the University Eye Hospital Freiburg according to the REAL classification and to correlate the tumour location, stage at presentation, lymphoma malignancy category, as well as tumour cell positivity for p53 and MIB-1 expression with the clinical outcome.

Material and methods
The archives of the eye pathology department of Freiburg were reviewed for lymphoproliferative lesions of the ocular adnexa. The paraffin blocks, containing formalin fixed specimens which were collected within the time period April 1976 to September 1998, were obtained and sections thereof stained with haematoxylin and eosin, periodic acid Schiff, and Giemsa. For immunohistochemistry an antigen retrieval method using pressure cooker or microwave was performed before immunohistochemical staining.13 The following monoclonal antibodies were used at the first stage incubation: CD20 (clone L26), CD21 (clone 1F8), CD43 (clone DF-T1), BCL protein 2 (clone 124), VS38c, p53 (clone DO-7), pancytokeratin marker MNF116 from Dako (Glostrup, Denmark), CD5 (clone UCHT2), Ki-67 antibody MNF116 from Dako, CD23 (clone 1B12) from Novocastra (Newcastle upon Tyne, UK). Polyclonal antibodies were used to examine the positivity for CD3 antigen and the immunoglobulin chains kappa, lambda, IgM, and IgD (Dako). The PAP method was used for the demonstration of immunoglobulin (Ig) molecule light chains kappa and lambda (Dako), heavy chains IgM and IgD (Dako), as well as the human p53 protein (Dako) and the APAAP method14 for the other antibodies. Based on the morphological features and immunophenotype, the lesions were subtyped according to the REAL classification10 by two of us (SEC and ASG) without knowledge of the previous diagnosis or of the clinical outcome. The number of MIB-1 and p53 protein positive cells was determined by counting the number of cells with nuclear positivity for these markers per 5 ×100 tumour cells using the 40× objective. With regard to the patients’ outcome, information was either obtained from the clinical files or contact was made with the patients’ ophthalmologist or general practitioner. Clinical staging of the lymphomas was undertaken according to Ann Arbor classification.15 Staging investigations included x ray examination, abdominal sonography, and bone marrow biopsy or computed tomograph scans and bone marrow biopsy, depending on the date of presentation. Stage I disease included both unilateral or bilateral ocular adnexal lesions without evidence of nodal involvement. “Primary disease” was defined as primary involvement of the ocular adnexa. “Secondary disease” was defined as a lymphomatous infiltration of the ocular adnexa by an identical lymphoma of another primary site.

Results
A review of the archives revealed 53 OAL of 46 patients with an age range of 32–89 years, the average age being 63 years. The patient collective consisted of 29 females and 17 males. The average follow up time was 84.7 months (range 2.4–239 months; median 61 months). The OAL occurred in the orbit (n=22), lid (n=11), conjunctiva (n=18), lacrimal sac (n=1), and sclera (n=1). Lymphoproliferative lesions of the ocular adnexa with morphological and immunohistological criteria of RLH were excluded from the study.

Histological results
The various subtypes of lymphoma were diagnosed and their location and the extent of disease are summarised in Table 1. The most common lymphoma was the EMZL, occurring in 38 specimens of 31 patients. Histologically, these tumours showed numerous secondary follicles with a broadening of the marginal zone by small centrocyte-like cells with occasional intermingled blasts. Frequently, the tumour cells displayed a plasmacellular differentiation and infiltrated reactive follicle centres (Fig 1A and B) or adjacent epithelium with the formation of lymphoepithelial lesions (Fig 1C). Ten of these 38 EMZL were previously diagnosed as RLH, seven as lymphoplasmacytoid immunocytoma, four as centroblastic centrocytic B cell lymphoma (the REAL equivalent being follicle centre lymphoma), and five as “low grade malignant B cell lymphoma”. The remaining specimens had been initially diag-
Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification

Different therapeutic regimens were applied—excision, radiotherapy, chemotherapy, and various combinations of these. The dosage of radiotherapy varied between 4 and 50 Gy; the most common chemotherapeutics used included cyclophosphamide, vincristine and prednisone. The stage at final follow up and the treatment modality applied are shown in Table 2. While 19 of 31 patients (59%) with an EMZL achieved complete remission after therapy, 10 had persistent tumour in the following clinical stages: stage I (n=2), stage III (n = 3), and stage IV (n = 5). In two patients the stage at final follow up was not known. Interestingly, one female patient with a bilateral orbital EMZL, who had been treated with radiotherapy, developed a DLCL of the conjunctiva 7 years later.

Complete remission was achieved in only two of six patients (33%) with non-EMZL low grade malignant lymphomas. Persistent tumour was seen in three patients with non-EMZL low grade malignant lymphomas, two of whom notably had mantle cell lymphoma. Complete remission was achieved in eight patients, whose specimens were previously diagnosed as RLH, after treatment in the form of surgical excision (n=7) and radiotherapy (n=1). Two patients, however, had recurrences before complete remission was achieved. Three of nine patients (33%) with a high grade malignant lymphoma achieved complete remission; however, five others (56%) had stage IV at final follow up; in one patient the stage was unclear.

Complete remission was achieved, therefore, in 24 of the original 46 patients (52%) and persistent tumour was seen in 18 patients (39%) after an average follow up period of 85 months. Five patients, in whom a complete remission had been initially achieved, died of causes unrelated to their lymphoma. Six patients with persistent tumour at final follow up were still alive at the time of our investigation (stage I: n=2, stage III: n=3, stage IV: n=1), 12 patients died of lymphoma related causes (EMZL, five patients; lymphoplasma- cytic lymphoma/immunocytoma, one; mantle cell lymphoma, one; diffuse large B cell lymphoma, four; and systemic T cell lymphoma, one) (Table 2). Ten of the 36 patients (27%) with a primary manifestation developed systemic involvement after 95 months on average.

TUMOUR MANIFESTATION AND LOCATION
A primary lymphoma manifestation was observed in 27 of 37 patients with “low grade malignant” category lymphomas (73%) and in seven of nine patients with the “high grade malignant” category lymphomas (78%). The primary lymphomas occurred in the orbit in 17 specimens, in the conjunctiva in 13, in the lid in eight, and in the sclera in one. Ten patients (22% of all patients) had a secondary manifestation: four in the orbit, three in the conjunctiva, three in the lid (Table 1).

STAGE AT PRESENTATION
Most patients had stage IE at initial presentation: 81% with low grade malignant category lymphomas and 67% with high grade malignant category lymphomas (Table 2). No significant correlation was found between the lymphoma category of malignancy and the stage at initial manifestation in the ocular adnexa (p=0.5).

TREATMENT, STAGE AT FINAL FOLLOW UP, AND CLINICAL OUTCOME
Different therapeutic regimens were applied—excision, radiotherapy, chemotherapy, and various combinations of these. The dosage of radiotherapy varied between 4 and 50 Gy; the

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total (no of specimens)</th>
<th>Orb</th>
<th>Conjunctiva</th>
<th>Lid</th>
<th>Others</th>
<th>Total (no of patients)</th>
<th>Primary</th>
<th>Later systemic involvement</th>
<th>Secondary</th>
<th>Unclear</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMZL</td>
<td>38</td>
<td>16</td>
<td>15</td>
<td>7</td>
<td>0</td>
<td>31</td>
<td>18</td>
<td>6</td>
<td>5</td>
<td>2*</td>
</tr>
<tr>
<td>DLCL</td>
<td>8</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>1*</td>
</tr>
<tr>
<td>FCL</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>MCL</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PCT</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LPCI</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>STL</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

*EMZL or DCLC with primary manifestation, the outcome was not known.

Correlation between lymphoma malignancy categories, clinical signs, and the clinical outcome
The stage at initial manifestation, as well as the lymphoma malignancy category, showed a sig-
significant correlation with the final course (p=0.0001 and p=0.03, respectively, Fig 2 and 3). Although statistically not significant, a difference in the course of the ocular adnexal lymphomas was noted depending on their location (p=0.4). Complete remission was achieved in 45% of the orbital cases, in 39% of the conjunctival cases, and in 18% of the lid lymphomas. Death related to lymphoma was the final course in 14%, 22%, and 36% of patients with lymphomas located at the orbit, conjunctiva, and lid, respectively (Table 3).

**CORRELATION BETWEEN THE POSITIVITY OF IMMUNOHISTOCHEMICAL MARKERS AND THE CLINICAL OUTCOME**

The percentage of Ki-67 antigen expression correlated significantly with the final outcome (p<0.05). Lymphomas of the low grade malignant category demonstrated an average Ki-67 antigen positivity of 5% (range 0–20%) (Fig 1H), whereas those of the high grade malignant category had an average Ki-67 antigen positivity of 42% (range 18–60%). The difference between both groups is statistically

---

**Figure 1**  
(A) Extranodal marginal zone lymphoma with a broadened marginal zone and infiltration of a reactive follicle with small centrocytoid tumour cells (Giemsa, ×200).  
(B) Remnants of a reactive follicle staining positively with CD23 (follicle dendritic cells, arrows), surrounded by infiltrating small centrocytoid lymphoma cells (×400).  
(C) Lymphoepithelial lesions, the epithelial cells stained positively with antibodies for pancytokeratin (×200).  
(D) Diffuse large cell B cell lymphoma showing a diffuse proliferation of lymphoblasts and a mitosis (arrows) (Giemsa, ×400).  
(E) Lymphoplasmacytic lymphoma/immunocytoma with Dutcher bodies (arrows) (Giemsa, ×1000).  
(F) Mantle cell lymphoma with tumour cells of intermediate size without blasts and with intermingled pale staining dendritic cells (Giemsa, ×400).  
(G) Localised plasmacytoma of the sclera (Giemsa, ×400).  
(H) Extranodal marginal zone lymphoma with a Ki-67 antigen positivity of 10% (×400, arrows: positive stained nuclei of lymphoma cells).
Table 2  Stage at diagnosis and stage at final follow up, depending on treatment (number of patients)

<table>
<thead>
<tr>
<th>Stage at diagnosis</th>
<th>Stage at final follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>Stage II</td>
</tr>
<tr>
<td>Complete remission</td>
<td>Stage I</td>
</tr>
<tr>
<td>EMZL</td>
<td>26</td>
</tr>
<tr>
<td>Other low grade malignancy (incl MCL)</td>
<td>4</td>
</tr>
<tr>
<td>MCL</td>
<td>1</td>
</tr>
<tr>
<td>High grade malignancy</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>36</td>
</tr>
</tbody>
</table>

*In one case two recurrences after excision alone, complete remission/stage I following radiotherapy. E = excision, R = radiotherapy, C = chemotherapy; bold numbers = patients whose death was related to lymphoma.

Table 3  Location of tumour and outcome

<table>
<thead>
<tr>
<th>Orbit (22)</th>
<th>Conjunctiva (18)</th>
<th>Lid (11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete remission</td>
<td>10 (45%)</td>
<td>7 (39%)</td>
</tr>
<tr>
<td>Persistent tumour</td>
<td>3 (14%)</td>
<td>2 (11%)</td>
</tr>
<tr>
<td>Recurrence</td>
<td>1 (5%)</td>
<td>3 (17%)</td>
</tr>
<tr>
<td>Death related to lymphoma</td>
<td>3 (14%)</td>
<td>4 (22%)</td>
</tr>
<tr>
<td>Death not related to lymphoma</td>
<td>2 (9%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>Lost to follow up</td>
<td>2 (9%)</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Death of unknown cause</td>
<td>1 (5%)</td>
<td>0</td>
</tr>
</tbody>
</table>

Note: The two remaining tumours of the 53 specimen were located in the lacrimal sac and sclera.

cases had been previously diagnosed as RLH. A revision of the original diagnosis could be made, however, on the basis of the morphology and the immunophenotype of the infiltrating cells, in particular, the demonstration of a monotypical expression of either the light or heavy chains of the immunoglobulin molecules. This relatively high proportion of lymphoma cases with the former diagnosis RLH exemplifies the difficulty in distinguishing RLH and many EMZL on the basis of conventional histology. EMZL was only described as an entity in 1983 by Isaacs and coworkers, and, therefore, it can be assumed that many EMZL of the ocular adnexa (and other sites) were misdiagnosed as RLH before this description. It would also explain the relatively high incidence of reported progression of RLH of the ocular adnexa into systemic lymphoma (15–29%) described in the literature. Despite the original “misdiagnosis” of RLH in 10 specimen of eight patients in the current series, the patients were either treated with radiotherapy or complete excision, whereby complete remission was achieved. Although a recurrence occurred in two patients, systemic disease was not observed over a follow up period of 172 months, which is significantly longer than the average follow up time of all patients (85 months).

Of the patients with an EMZL of the ocular adnexa, 84% had primary disease and 16% a secondary lymphomatous manifestation. Similar data were obtained in two previous larger studies. The EMZL occurred with equal frequency in the orbit and conjunctiva (40%), but less frequently in the lid (20%). Although almost identical results were published by other authors, this distribution is surprising considering that, in contrast to the conjunctiva, orbital soft tissue does not contain any intrinsic lymphoid tissue.

The second most common lymphoma subtype in the current series was the DLCL, different from an investigation of 99 OAL previously conducted by one of us, which demonstrated follicle centre lymphoma as being the second most common subtype (10 cases), followed by DLCL (nine cases). Combination of the two separate lymphoma collections, however, confirms DLCL as being second in frequency in these tissues. A further difference between these two studies was the finding by Coupland et al, that DLCL of the ocular adnexa occurred only in patients with lymphomatous disease stage II or above. In the current study, six of the eight patients with
DLCL of the ocular adnexa presented initially with stage I disease. Two of these patients later developed systemic disease, despite radiotherapy and, in one patient, adjuvant chemotherapy. The discrepancies between the two investigations could possibly be explained by the near majority of the DLCL occurring in the orbit in the earlier series, resulting in relatively late presentation in some cases. Further, one patient was proved to be HIV positive and this lymphoma showed a particularly aggressive course. The findings of the present series are comparable, however, to those of White et al, who reported six of seven patients with DLCL with stage I. Despite this, it must be emphasised that primary DLCL of the ocular adnexa should be regarded with mistrust and that, following radiotherapy, regular patient contact has to be maintained (for example, 6 monthly appointments for the first 2 years).

Various therapeutic regimens were applied in the current series. Patients with stage I disease were treated with surgical excision, radiotherapy, chemotherapy, or a combination of the above. All patterns achieved satisfactory results with various success rates for different lymphoma types. Patients with a lymphoma-tous disease of stage II or higher had a poorer outcome compared with those with stage I disease, irrespective of the kind of therapeutic regimen applied. Baldini et al noted good responses of stage I lymphomas to radiotherapy, while we observed a satisfying outcome for all therapeutic regimens, including surgical excision alone in lymphomas of low grade malignancy. It should be noted, however, that more recurrences were observed following surgical excision alone compared with radiotherapy.

Statistical analysis of the lymphoma malignancy category and the stage of disease at manifestation in the ocular adnexa did not prove to be significant (p=0.5). This can probably be accounted for by the relatively large number of cases of DLCL with stage I disease in comparison with other studies. However, a significant relation between lymphoma malignancy grade and the prognosis was found (p=0.03). These results are supported by Coupland et al, but not by other authors. On the other hand, the subdivision of the primary OAL into EMZL and “other” lymphoma subtypes did not reveal a significant difference in primary (p=0.5), as reported by White et al and Baldini et al. These results are, however, contrary to those of Cahill et al, who found a better prognosis of primary EMZL compared with other lymphoma subtypes. Immunohistological markers which were demonstrated in this study to have significant prognostic value were Ki-67 antigen and p53 protein expression. The positivity of the tumour cells for Ki-67 antigen and p53 protein showed a significant correlation with the lymphoma malignancy category, as well as with the final outcome (p<0.001 and p<0.05). Similar findings were presented recently in a previous study. CDS (a T cell antigen which can be aberrantly expressed by some B cell lymphomas) was proposed as another prognostic marker for EMZL in the ocular adnexa as well as in other locations. CD5 positivity should be correlated with persistent or recurrent disease. We could not demonstrate this association in our small number of CD5 positive EMZL.

Although statistically not significant (p=0.4), the current investigation found a difference in the patients’ outcome depending on tumour location. The orbital and conjunctival lymphomas seem to have a better prognosis compared with the lymphomas of the lid. Other authors found that the lid lymphomas had a significantly worse prognosis compared with those of the orbit and conjunctiva; the latter having the best prognosis overall. This point is controversial in the literature as other studies did not find any difference in outcome according to tumour location. From our reclassification study of OAL, we can support the findings of other studies that EMZL is the most common lymphoma subtype to occur in these locations and that EMZL, in general, has a favourable prognosis. The stage at diagnosis, the lymphoma malignancy category, as well as Ki-67 antigen and p53 protein expression have prognostic value with regard to the final outcome in recurrent disease. A complete remission was obtained in approximately 75% of our patients with a primary EMZL following treatment. Surgical excision, as well as radiotherapy, led to complete remission, nevertheless more local recurrences were observed in those treated by surgical excision alone. Thus, primary EMZL would be treated best with an excisional biopsy, where possible, combined with radiotherapy. Primary DLCL should be treated at least with the identical regimen combined, however, with more intensive follow up investigations. Further studies are required to better understand the pathogenesis of lymphomas, particularly EMZL, in the ocular adnexa in the hope of optimising their treatment.

We thank M Oschewski (Institut für Medizinische Biometrie und Medizinische Informatik, Freiburg, Germany) for the survival analysis.

Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification


